logo
Plus   Neg
Share
Email
Comment

Novavax RSV Vaccine Mid-Stage Trial Shows Positive Results

Shares of Novavax Inc.(NVAX) rose over five percent in after-hours trade Tuesday after its mid-stage study of a vaccine for the treatment of respiratory diseases in women of childbearing age met trial goals.

Top-line data from the phase II trial of respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age accomplished the trial's protocol-specified objectives and supports progression to the next stage of advanced clinical testing, the company said in a statement.

Novavax said the the antibodies in vaccinated women can be expected to be naturally transferred to their infants in utero and thereby may confer passive protection at the earliest stage of life when these infants are extremely vulnerable to severe respiratory disease due to the virus.

The mid-stage study enrolled 330 women of childbearing age who received either one or two injections of a single-dose of vaccine or placebo. The trial evaluated the safety and immunogenicity of two doses of vaccine with and without aluminum phosphate as an adjuvant.

Novavax said the vaccine was well-tolerated and the safety profile was similar to that observed in the early-stage clinical trial.

"These results confirm that our RSV vaccine candidate has the potential to induce clinically useful immunity and has raised no safety concerns. The primary immunogenicity measures confirmed that the vaccine is a potent antigen and the aluminum phosphate adjuvant further enhanced the antibody responses," said Gregory Glenn SVP and Chief Medical Officer of Novavax.

NVAX closed Tuesday's trading at $2.35, down $0.02 or 0.84%, on a volume of 1.8 million shares on the Nasdaq. The stock gained $0.13 or 5.53% in after-hours trade.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
BlackRock Inc., the world's largest asset manager, said it plans to speak with gun makers and distributors following public outcry after the Florida high school shooting that killed 17 people. BlackRock, which had $6.3 trillion in assets under management as of December 31, 2017, holds shares in gun makers Sturm Ruger & Co. Inc. as well as American Outdoor Brands Corp. An upgraded boarding in Southwest Airline will cost you more. The airline usually not assign seats to passengers, but one can choose from an open seat. The Upgraded Boarding will allow passengers to choose from A1 - A15 boarding positions. The cost for these positions would be $30, $40 and $50, depending on flight and route. This option can be availed from the ticket counter or gate. Citigroup Inc.'s co-head of mergers and acquisitions, Peter Tague, is leaving the company, according to media reports, citing people familiar with the matter. Tague has been co-head of Global M&A business at Citigroup since March 2012, alongside Cary Kochman and Mark Shafir. It was not immediately clear what Tague intends to do after he leaves Citigroup.
comments powered by Disqus
Follow RTT